Benign Gynecological Diseases and SERMs

Abad de Velasco L, Cano A (2003) Acute abdomen due to endometriosis in a premenopausal woman taking tamoxifen. Eur J Obstet Gynecol Reprod Biol 109:234–235 Akande VA, Hunt LP, Cahill DJ, Jenkins JM (2004) Differences in time to natural conception between women with unexplained infertility and infertile women with minor endometriosis. Hum Reprod 19:96–103 American Fertility Society (1985) Revised American Fertility Society classification of endometriosis: 1985. Fertil Steril 43:351–355 Baker VL, Draper M, Paul S, Allerheiligen S, Glant M, Shifren J, Jaffe RB (1998) Reproductive endocrine and endometrial hydrochloride, a selective estrogen receptor modulator, in women with regular menstrual cycles. J Clin Endocrinol Metab 83: 6–13 Barbieri RL (1997) Reduction in the size of a uterine leiomyoma following discontinuation of an estrogen-progestin contraceptive. Gynecol Obstet Invest 43:276–277 Benassayag C, Leroy MJ, Rigourd V, Robert B, Honore JC, Mignot TM (1999) Estrogen receptors (ERalpha/ERbeta) in normal and pathological growth of the human myometrium: pregnancy and leiomyoma. Am J Physiol 276:1112–1118 Bese T, Simsek Y, Bese N, Ilvan S, Arvas M (2003) Extensive pelvic endometriosis with malignant change in tamoxifen-treated postmenopausal women. Int J Gynecol Cancer 13:376–380 Black LJ, Sato M, Rowley ER, Magee DE, Bekele A, Williams DC (1994) Raloxifene (LY139481 HCL) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovriectomized rats. J Clin Invest 93:63–69 Brandon DD, Erickson TE, Keenan EJ, Strawn EY, Novy MJ, Burry KA (1995) Estrogen receptor gene expression in human uterine leiomyomata. J Clin Endocrinol Metab 80:1876–1881 Bryant HU, Glasebrook AL, Yang NN, Sato M (1996) A pharmacological review of raloxifene. J Bone Miner Metab 14:1–9 Bulun SE, Simpson ER, Word RA (1994) Expression of the CYP19 gene and its product aromatase cytochrome P450 in human uterine leiomyoma tissue and cells in culture. J Clin Endocrinol Metab 78:736–743 Carter JE (1998) Surgical treatment for chronic pelvic pain. J Soc Laparoendoscop Surgeons 2:129–133 Chang CK, Chen P, Leu FJ, Lou SM (2003) Florid polypoid endometriosis exacerbated by tamoxifen therapy in breast cancer. Obstet Gynecol 102:1127–1130 Check JH (2003a) The association of minimal and mild endometriosis without adhesions and infertility with therapeutic strategies. Clin Exp Obstet Gynecol 30:13–18 Check JH (2003b) The association of minimal and mild endometriosis without adhesions and infertility with therapeutic strategies. Clin Exp Obstet Gynecol 30:19–34 Check JH (2003c) The association of minimal and mild endometriosis without adhesions and infertility with therapeutic strategies. Clin Exp Obstet Gynecol 30:35–39 Chegini N, Rong H, Dou Q, Kipersztok S, Williams RS (1996) Gonadotropin-releasing hormone (GnRH) and GnRH receptor gene expression in human myometrium and leiomyomata and the direct action of GnRH analogs on myometrial smooth muscle cells and interaction with ovarian steroids in vitro. J Clin Endocrinol Metab 81:3215–3221 Child TJ, Tan SL (2001) Endometriosis: aetiology, pathogenesis and treatment. Drugs 61:1735–1750 Chwalisz K, Garg R, Brenner RM, Schubert G, Elger W (2002) Selective progesterone receptor modulators (SPRMs): a novel therapeutic concept in endometriosis. Ann NY Acad Sci 955:373–388 Cohen FJ, Watts S, Shah A, Akers R, Plouffe L (2000) Uterine effects of 3-year raloxifene therapy in postmenopausal women younger than age 60. Obstet Gynecol 95:104–110 Cohen I, Beyth Y, Shapira J, Tepper R, Fishman A, Cordoba M, Bernheim J, Yigael D, Altaras MM (1997) High frequency of adenomyosis in postmenopausal breast cancer patients treated with tamoxifen. Gynecol Obstet Invest 44:200–205 Coutinho EM (1989) Gestrinone in the treatment of myomas. Acta Obstet Gynecol Scand 150:39–46 Coutinho EM (1990) Treatment of large fibroids with high doses of getrinone. Gynecol Obstet Invest 30:44–47 Coutinho EM, Goncalves MT (1989) Long-term treatment of leiomyomas with gestrinone. Fertil Steril 51:939–946 Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC (1999) Effects of raloxifene on breast cancer risk in postmenopausal women. J Am Med Assoc 281:2189–2197 De Leo V, La Marca A, Morgante G (1999) Short-termtreatment ofuterine fibromyomas with danazol. Gynecol Obstet Invest 47:258–262 De Leo V, La Marca A, Morgante G, Severi FM, Petraglia F (2001) Administration of somatostatin analogue reduces uterine and myoma volume in women with uterine leiomyomata. Obstet Gynecol 75:632–633 Demco L (1998) Mapping the source and character of pain due to endometriosis by patient-assisted laparoscopy. J Am Assoc Gynecol Laparosc 5:241–245 D’Hooghe TM (2003) Immunomodulators and aromatase inhibitors: are they the next generation of treatment for endometriosis? Curr Opin Obstet Gynecol 15: 243–249 D’Hooghe TM, Debrock S, Hill JA, Meuleman C (2003) Endometriosis and subfertility: is the relationship resolved? Semin Reprod Med 21:243–254 Dilts PV Jr, Hopkins MP, Chang AE, Cody RL (1992) Rapid growth of leiomyoma in patient receiving tamoxifen. Am J Obstet Gynecol 166:167–168 Englund K, Blanck A, Gustavsson I, Lundkvist U, Sjoblom P (1998) Sex steroids receptors in human myometrium and fibroids: changes during the menstrual cycle and gonadotropin-releasing hormone treatment. J Clin Endocrinol Metab 83:92–96 Ettinger B, Black DM, Mitlak BH, Knickerbocker RH, Nickelsen T, Genant NK (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. J Am Med Assoc 282:637–645 Fotiou S, Tserkezoglou A, Hadjieleftheriou G, Apostolikas N, Karydas I, Stravolemos K (1998) Tamoxifen associated uterine pathology in breast cancer patients with abnormal bleeding. Anticancer Res 18:625–629 Friedman AJ, Thomas PP (1995) Does low-dose combination oral contraceptive use affect uterine size or menstrual flow in premenopausal with leiomyomas? Obstet Gynecol 85:631–635 Fuchs-Young R, Howe S, Hale L, Miles R, Walker C (1996) Inhibition of estrogen stimulated growth of uterine leiomyomas by selective estrogen receptor modulators. Mol Carcinog 17:151–159 Gainer EE, Ulmann A (2003) Pharmacologic properties of CDB(VA)-2914. Steroids 68:1005–1011 Gao Z, Matsuo H, Wang Y, Nakago S, Maruo T (2001) Up-regulation by IGF-I of proliferating cell nuclear antigen and Bcl-2 protein expression in human uterine leiomyoma cells. J Clin Endocrinol Metab 86:5593–5599 Goldstein SR, Scheele WH, Rajagopalan SK, Wilkie JL, Walsh BW, Parsons AK (2000) A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium. Obstet Gynecol 95:95–103 Gruppo Italiano per lo Studio dell’Endometriosi (2001) Relationship between stage, site and morphological characteristics of pelvis endometriosis and pain. Hum Reprod 16:2668–2671 Higashijima T, Kataoka A, Nishida T, Yakushiji M (1996) Gonadotropin-releasing hormone agonist therapy induces apoptosis in uterine leiomyoma. Eur J Obstet Gynecol Reprod Biol 68:169–173 Howe SR, Gottardis MM, Everitt JI, Walker C (1995) Estrogen stimulation and tamoxifen inhibition of leiomyoma cell growth in vitro and in vivo. Endocrinology 136:4996–5003 Hurd WW (1998) Criteria that indicate endometriosis is the cause of chronic pelvic pain. Obstet Gynecol 92:1029–1032 Jacobson TZ, Barlow DH, Koninckx PR, Olive D, Farquhar C (2004) Laparoscopic surgery for subfertility associated with endometriosis. Cochrane Library, Issue 4. Update Software, Oxford Jirecek S, Lee A, Pavo I, Crans G, Eppel W, Wenzl R (2004) Raloxifene prevents the growth of uterine leiomyomas in premenopausal women. Fertil Steril 81:132–136 Kawaguchi K, Fujii S, Konishi I, Nanbu Y, Nonogaki H, Mori T (1989) Mitotic activity in uterine leiomyomas during the menstrual cycle. Am J Obstet Gynecol 160:637–641 Kertel LM, Murphy AA, Morales AJ, Yen SS (1994) Clinical efficacy of antiprogesterone RU486 in the treatment of endometriosis and uterine fibroids. Hum Reprod 9:116–120 Khovidhunkit W, Shoback DM (1999) Clinical effects of raloxifene hydrocloride in women. Ann Intern Med 130:431–439 Kuiper GGJM, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, Gustafsson JA (1997) Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology 138:863–870 Lacreuse A, Wilson ME, Herndon JG (2002) Estradiol, but not raloxifene, improves aspects of spatial working memory in aged ovariectomized rhesus monkeys. Neurobiol Ag 23:589–600 Lefebvre G, Allaire C, Jeffrey J (2002) Clinical Practice Gynaecology Committee and Executive Committeee and Council, Society of Obstetricians and Gynaecologists of Canada. SOGC clinical guidelines. Hysterectomy. J Obstet Gynaecol Can 4:37–61 Leo L, Lanza A, Re A, Tessarolo M, Bellino R, Lauricella A, Wierdis T (1994) Leiomyomas in patients receiving tamoxifen. Clin Exp Obstet Gynecol 21:94–98 Lumsden MA, West CP, Baird DT (1989a) Tamoxifen prolongs luteal phase in premenopausal women but has no effect on the size of uterine fibroids. Clin Endocrinol 31:335–343 Lumsden MA, West CP, Hillier H, Baird DT (1989b) Estrogenic action of tamoxifen in women treated with luteinizing hormone-releasing hormone agonists (goserelin)-lack of shrinkage of uterine fibroids. Fertil Steril 52:924–929 MacDonald SR, Klock SC, Milad MP (1999) Long-term outcome of nonconservative surgery (hysterectomy) for endometriosis-associated pain in women < 30 years old. Am J Obstet Gynecol 180:1360–1363 Maeda T, Ke HZ, Simmons H, Thompson D (2004) Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies. Clin Calcium 14:85–93 Marcoux S, Maheux R, Berube S (1997) Laparoscopy surgery in infertile woman with minimal or mild endometriosis. Canadian Collaborative Group on Endometriosis. N Engl J Med 337:217–222 Marshall LM, Spiegelman D, Goldman MB, Manson JE, Colditz G, Barbieri RL, Stampfer MJ, Hunter DJ (1998) A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata. Fertil Steril 70:432–439 Minakuchi K, Kawamura N, Tsujimura A (1999) Remarkable and persistent shrinkage of uterine leiomyoma associated with interferon alfa treatment for hepatitis. Lancet 353:2127–2128 Missmer SA, Cramer DW (2003) The epidemiology of endometriosis. Obstet Gynecol Clin North Am 30:1–19 Murphy AA, Kettel LM, Morales AJ, Roberts VJ, Yen SSC (1993) Regression of uterine leiomyomata in response to the antiprogesterone RU 486. J Clin Endocrinol Metab 76:513–517 Olive DL (2002) Role of progesterone antagonists and new selective progesterone receptor modulators in reproductive health. Obstet Gynecol Surv 57:S55–63 Olive DL, Pritts EA (2001) Treatment of endometriosis. N Engl J Med 345:266–275 Oral E, Arici A (1997) Pathogenesis of endometriosis. Obstet Gynecol Clin North Am 24:219–233 Paech K, Webb P, Kuiper GGJM, Nilsson S, Gustafsson J, Kushner PJ, Scanlan TS (1997) Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites. Science 277:1508–1510 Palomba S, Zullo F (2006b) Pelvic denervations procedures as surgical management of pelvic pain due to endometriosis. In: Sutton C, Jones K, Adamdson GD (eds) Modern Management of Endometriosis. Taylor and Francis, London; 167–176; Palomba et al. 2006a Palomba S, Affinito P, Tommaselli GA, Nappi C (1998) Aclinical trial on the effects of tibolone association with gonadotropin-releasing hormone analogues for the treatment of uterine leiomyomata. Fertil Steril 70:111–118 Palomba S, Affinito P, Di Carlo C, Bifulco G, Nappi C (1999) Long term administration of tibolone plus gonadotropin-releasing hormone agonist for treatment of uterine leiomyomas: effectiveness and effects on vasomotor symptoms, bone mass, and lipid profile. Fertil Steril 72:889–895 Palomba S, Sammartino A, Di Carlo C, Affinito P, Zullo F, Nappi C (2001) Effects of raloxifene treatment on uterine leiomyomas in postmenopausal women. Fertil Steril 76:38–43 Palomba S, Orio F Jr, Morelli M, Russo T, Pellicano M, Zupi E, Lombardi G, Nappi C, Benedetti Panici PG, Zullo F (2002a) Raloxifene administration in premenopausal women with uterine leiomyomas: a pilot study. J Clin Endocrinol Metab 87:3303–3308 Palomba S, Russo T, Orio F jr, Tauchmananovà L, Zupi E, Benedetti Panici PG, Nappi C, Lombardi G, Colao A, Zullo F (2002b) Effectiveness of combined GnRH analogue plus raloxifene administration in the treatment of uterine leiomyomas: a prospective, randomized, single-blind, placebo-controlled clinical trial. Hum Reprod 17:3213–3219 Palomba S, Orio F Jr, Morelli M, Russo T, Pellicano M, Nappi C, Mastrantonio P, Lombardi G, Colao A, Zullo F (2002c) Raloxifene administration in women treated with gonadotropin releasing hormone agonist for uterine leiomyomas: effects on bone metabolism. J Clin Endocrinol Metab 87:4476–4481 Palomba S, Zullo F, Orio F Jr, Lombardi G (2004a) Does raloxifene inhibit the growth of uterine fibroids? Fertil Steril 81:1719–1720 Palomba S, Russo T, Orio F Jr, Sammartino A, Sbano FM, Nappi C, Colao A, Mastrantonio P, Lombardi G, Zullo F (2004b) Lipid, glucose, and homocysteine metabolism in women treated with a gonadotropin-releasing hormone agonist with or without raloxifene. Hum Reprod 19:415–421 Palomba S, Orio F Jr, Russo T, Falbo A, Cascella T, Doldo P, Nappi C, Lombardi G, Mastrantonio P, Zullo F (2004c) Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas. Hum Reprod 19:1308–1314 Palomba S, Orio F Jr, Falbo A, Russo T, Amati A, Zullo F (2005b) Gonadotropin-releasing hormone agonist with or without raloxifene: effects on cognition, mood, and quality of life. Fertil Steril 84:154–161 Palomba S, Falbo A, Russo T, Zullo F (2005a) Emerging drugs in uterine leiomyomas. Exp Opin Emerg Drugs (in press) Palomba S, Falbo A, Russo T, Zullo F (2006a) GnRH analogs use for the treatment of symptomatic leiomyomas. Gynecol Surg 2:7–13 Palomba S, Orio F Jr, Russo T, Falbo A, Tolino A, Lombardi G, Cimini V, Zullo F (2005b) Anti-proliferative and pro-apoptotic effects of raloxifene on uterine leiomyomas in postmenopausal women. Fertil Steril (in press) Parazzini F (1999) Ablation of lesions or no treatment in minimal-mild endometriosis in infertile women: a randomized trial. Gruppo Italiano per lo Studio dell’Endometriosi. Hum Reprod 14:1332–1334 Parrott E, Butterworth M, Green A, White INH, Greaves P (2001) Adenomyosis: a result of disordered stromal differentiation. Am J Pathol 159:623–630 Pasqualini JR, Cornier E, Grenier J, Vella C, Schatz B, Netter A (1990) Effect of decapeptyl, an agonost analog of gonadotropin-releasing hormone on estrogens, estrogen sulfates, and progesterone receptors in leiomyomata and myometrium. Fertil Steril 53:1012–1017 Pickersgill A (1998) GnRH agonists and add-back therapy: is there a perfect combination? Br J Obstet Gynaecol 105:475–485 Porpora MG, Gomel V (1997) The role of laparoscopy in the management of pelvic pain in women of reproductive age. Fertil Steril 68:765–769 Porter KB, Tsibris JC, Porter GW, Fuchs-Young R, Nicosia SV, O’Brien WF (1998) Effects of raloxifene in a guinea pig model for leiomyomas. Am J Obstet Gynecol 179:1283–1287 Rannestad T, Eikeland OJ, Helland H (2001) The quality of life in women suffering from gynecological disorders is improved by means of hysterectomy. Absolute and relative differences between pre-and postoperative measures. Acta Obstet Gynecol Scand 80:46–51 Rein MS (2000) Advanced in uterine leiomyoma research: the progesterone hypothesis. Environ Health Perspect 108:791–793 Rein MS, Barbieri RL, Friedman AJ (1995) Progesterone: a critical role in pathogenesis of uterine myomas. Am J Obstet Gynecol 172:14–18 Riggs BL, Hartmann LC (2003) Selective estrogen-receptor modulators: mechanisms of action and application to clinical practice. N Engl J Med 348:618–629 Rivera JA, Christopoulos S, Small D, Trifiro M (2004) Hormonal manipulation of benign metastasizing leiomyomas: report of two cases an review of the literature. J Clin Endocrinol Metab 89:3183–3188 Robertson JF (2004) Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective. Cancer Treat Rev 30:695–706 Rose PG, Alvarez B, Maclennan GT (2000) Exacerbation of endometriosis as a result of premenopausal tamoxifen exposure. Am J Obstet Gynecol 183:507–508 Sadan O, Ginath S, Sofer D, Rotmensch S, Debby A, Glezerman M, Zakut H (2001) The role of tamoxifen in the treatment of symptomatic uterine leiomyomata: a pilot study. Eur J Obstet Gynecol Reprod Biol 96:183–186 Saito T, Yoshizawa M, Yamauchi Y, Kinoshita S, Fujii T, Mieda M, Sone H, Yamamoto Y, Koizumi N (2003) Effects of the novel orally active antiestrogen TZE-5323 on experimental endometriosis. Arzneimittelforschung 53:507–514 Schwartz LB, Rutkowski N, Horan C, Nachtigall LE, Snyder J, Goldstein SR (1998) Use of transvaginal ultrasonography to monitor the effects of tamoxifen on uterine leiomyoma size and ovarian cyst formation. J Ultrasound Med 17: 699–703 Shozu M, Murakami K, Segawa T, Kasai T, Inoue M (2003) Successful treatment of a symptomatic uterine leiomyoma in a perimenopausal woman with a nonsteroidal aromatase inhibitor. Fertil Steril 79:628–631 Spitz IM (2003) Progesterone antagonists and progesterone receptor modulators: an overview. Steroids 68:981–993 Steward EA (2001) Uterine fibroids. Lancet 357:293–298 Stones RW, Mountfield J (2004) Interventions for treating chronic pelvic pain in women. Cochrane Library, Issue 2. Update Software, Oxford Sutton CJ, Ewen SP, Whitelaw N (1994) Prospective, randomized double-blind controlled trial of laser laparoscopy in the treatment of pelvic pain associated with minimal, mild and moderate endometriosis. Fertil Steril 62:696–700 Tiltman AJ (1985) The effect of progestins on the mitotic activity of uterine fibromyomas. Int J Gynecol Pathol 4:89–96 Tomas E, Kauppila A, Blanco G, Apaja-Sarkkinen M, Laatikainen T (1995) Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients. Gynecol Oncol 59:261–266 Ugwumadu AH, Harding K (1994) Uterine leiomyomata and endometrial proliferation in postmenopausal women treated with the anti-oestrogen tamoxifen. Eur J Obstet Gynecol Reprod Biol 54:153–156 Walker CL, Burroughs KD, Davis B, Sowell K, Everitt JI, Fuchs-Young R (2000) Preclinical evidence for therapeutic efficacy of selective estrogen receptor modulators for uterine leiomyoma. J Soc Gynecol Invest 7:249–256 Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, Shah AS, Anderson PW (1998) Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. J Am Med Assoc 279:1445–1451 Yaffe K, Krueger K, Sarkar S, Grady D, Barrett-Connor E, Cox DA, et al. (2001) Cognitive function in postmenopausal women treated with raloxifene. N Engl J Med 344:1207–1213 Yamamoto T, Takamori K, Okada H (1984) Estrogen biosynthesis in leiomyomata and myometrium of the uterus. Horm Metab Res 16:678–679 Author information Authors and Affiliations Editor information Editors and Affiliations Rights and permissions Copyright information © 2006 Springer-Verlag Berlin Heidelberg About this chapter Cite this chapter Palomba, S., Zullo, F. (2006). Benign Gynecological Diseases and SERMs. In: Sanchez, A.C., Calaf i Alsina, J., Dueñas-Díez, JL. (eds) Selective Estrogen Receptor Modulators. Springer, Berlin, Heidelberg . https://doi.org/10.1007/3-540-34742-9_12 Download citation DOI: https://doi.org/10.1007/3-540-34742-9_12 Publisher Name: Springer, Berlin, Heidelberg Print ISBN: 978-3-540-24227-7 Online ISBN: 978-3-540-34742-2 eBook Packages: MedicineMedicine (R0)

These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.